Literature DB >> 2453793

The ability of Sephadex to activate human complement is suppressed in specifically substituted functional Sephadex derivatives.

M P Carreno1, D Labarre, M Jozefowicz, M D Kazatchkine.   

Abstract

The capacity of Sephadex and of chemically substituted Sephadex derivatives to activate human complement was examined by incubating polymer particles in normal human serum (NHS) under conditions that allow classical and/or alternative pathway activation, and by determining complement consumption or generation of C3a antigen in serum. Sephadex was found to activate complement in NHS, mainly through the alternative pathway. The complement-activating capacity of Sephadex was directly related to the surface area of polymer that could interact with serum. Substitution of hydroxyl groups of Sephadex with carboxymethyl (CM) groups suppressed the complement-activating capacity of the polymer in a dose-dependent fashion so that Sephadex bearing an average of one or more CM groups per saccharidic unit exhibited no complement-activating ability. Blocking of CM groups on CM sephadex with amide bonds did not restore a complement-activating capacity to the polymer, indicating that intact hydroxyl groups of the sugar units are required for complement activation by Sephadex. CM Sephadex was also found to adsorb C3adesArg which bound to the polymer with a calculated affinity of 1 x 10(6) l x M-1. Substitution of Sephadex with carboxymethyl and benzylamide sulphonate groups which confers to the polymer the capacity to catalyse thrombin inactivation on its surface also suppressed the complement-activating capacity of Sephadex. Sephadex derivatives that lack complement-activating properties and adsorb anaphylatoxins may provide useful models for the design of cellulosic membranes and biomaterials with blood compatible properties.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2453793     DOI: 10.1016/0161-5890(88)90064-8

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  8 in total

1.  Dynamics of avian inflammatory response to cross-linked dextran. Changes in avian blood leukocyte populations.

Authors:  K A Golemboski; S E Bloom; R R Dietert
Journal:  Inflammation       Date:  1990-02       Impact factor: 4.092

2.  Complement activation by core-shell poly(isobutylcyanoacrylate)-polysaccharide nanoparticles: influences of surface morphology, length, and type of polysaccharide.

Authors:  Isabelle Bertholon; Christine Vauthier; Denis Labarre
Journal:  Pharm Res       Date:  2006-05-25       Impact factor: 4.200

3.  Long-circulating nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate).

Authors:  C Passirani; G Barratt; J P Devissaguet; D Labarre
Journal:  Pharm Res       Date:  1998-07       Impact factor: 4.200

4.  Positively-charged, porous, polysaccharide nanoparticles loaded with anionic molecules behave as 'stealth' cationic nanocarriers.

Authors:  Archibald Paillard; Catherine Passirani; Patrick Saulnier; Maya Kroubi; Emmanuel Garcion; Jean-Pierre Benoît; Didier Betbeder
Journal:  Pharm Res       Date:  2009-10-23       Impact factor: 4.200

5.  Comparative study of in vitro inhibition of activation of the classical and alternative pathways of human complement by the magnesium and sodium salts of the anti-inflammatory peptide N-acetyl-aspartyl-glutamic acid (NAAGA).

Authors:  J Feuillard; F Maillet; P Goldschmidt; L Weiss; M D Kazatchkine
Journal:  Agents Actions       Date:  1991-03

6.  Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups.

Authors:  Carolina Salvador-Morales; Liangfang Zhang; Robert Langer; Omid C Farokhzad
Journal:  Biomaterials       Date:  2009-01-23       Impact factor: 12.479

7.  Activation of Human Complement System by Dextran-Coated Iron Oxide Nanoparticles Is Not Affected by Dextran/Fe Ratio, Hydroxyl Modifications, and Crosslinking.

Authors:  Guankui Wang; Fangfang Chen; Nirmal K Banda; V Michael Holers; LinPing Wu; S Moein Moghimi; Dmitri Simberg
Journal:  Front Immunol       Date:  2016-10-10       Impact factor: 7.561

Review 8.  Nanoparticle-Induced Complement Activation: Implications for Cancer Nanomedicine.

Authors:  Ninh M La-Beck; Md Rakibul Islam; Maciej M Markiewski
Journal:  Front Immunol       Date:  2021-01-08       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.